Skip to main content
Erschienen in: Tumor Biology 9/2014

01.09.2014 | Research Article

TPM3, a strong prognosis predictor, is involved in malignant progression through MMP family members and EMT-like activators in gliomas

verfasst von: Tao Tao, Yan Shi, Dongfeng Han, Wenkang Luan, Jin Qian, Junxia Zhang, Yingyi Wang, Yongping You, Chinese Glioma Cooperative Group (CGCG)

Erschienen in: Tumor Biology | Ausgabe 9/2014

Einloggen, um Zugang zu erhalten

Abstract

Recent studies have shown that many molecular mechanisms, such as the EGFR, AKT, STAT3, and beta-catenin pathways, are involved in glioma. However, the prognosis of the disease remains poor. Explorations of the underlying mechanisms of glioma and identification of effective markers for early diagnosis and accurate prognostication remain important today. In this study, we employed survival analysis to determine that TPM3 overexpression was significantly associated with high-grade gliomas and higher mortality. Using microarray combined with Pearson correlation analysis, we found that TPM3 was positively correlated with the expression of MMP family members and EMT-like activators. Reduction of TPM3 (via TPM3-siRNA) inhibited cellular invasion and migration and decreased MMP-9 and SNAI1 levels in glioma cells. To the best of our knowledge, our work is the first to show that TPM3 plays a critical role in the progression of gliomas and provides novel insights into the key roles of MMP family members and EMT-like activators that mediate TPM3 functional signaling for glioma regulation.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Wang Y, Jiang T. Understanding high grade glioma: molecular mechanism, therapy and comprehensive management. Cancer Lett. 2013;331:139–46.CrossRefPubMed Wang Y, Jiang T. Understanding high grade glioma: molecular mechanism, therapy and comprehensive management. Cancer Lett. 2013;331:139–46.CrossRefPubMed
2.
Zurück zum Zitat Pieples K, Arteaga G, Solaro RJ, et al. Tropomyosin 3 expression leads to hypercontractility and attenuates myofilament length-dependent Ca(2+) activation. Am J Physiol Heart Circ Physiol. 2002;283:H1344–53.CrossRefPubMed Pieples K, Arteaga G, Solaro RJ, et al. Tropomyosin 3 expression leads to hypercontractility and attenuates myofilament length-dependent Ca(2+) activation. Am J Physiol Heart Circ Physiol. 2002;283:H1344–53.CrossRefPubMed
3.
Zurück zum Zitat Zhu S, Si ML, Wu H, Mo YY. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem. 2007;282:14328–36.CrossRefPubMed Zhu S, Si ML, Wu H, Mo YY. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem. 2007;282:14328–36.CrossRefPubMed
4.
Zurück zum Zitat Kim TM, Yim SH, Shin SH, et al. Clinical implication of recurrent copy number alterations in hepatocellular carcinoma and putative oncogenes in recurrent gains on 1q. Int J Cancer. 2008;123:2808–15.PubMedCentralCrossRefPubMed Kim TM, Yim SH, Shin SH, et al. Clinical implication of recurrent copy number alterations in hepatocellular carcinoma and putative oncogenes in recurrent gains on 1q. Int J Cancer. 2008;123:2808–15.PubMedCentralCrossRefPubMed
5.
Zurück zum Zitat Miyado K, Kimura M, Taniguchi S. Decreased expression of a single tropomyosin isoform, TM5/TM30nm, results in reduction in motility of highly metastatic B16-F10 mouse melanoma cells. Biochem Biophys Res Commun. 1996;225:427–35.CrossRefPubMed Miyado K, Kimura M, Taniguchi S. Decreased expression of a single tropomyosin isoform, TM5/TM30nm, results in reduction in motility of highly metastatic B16-F10 mouse melanoma cells. Biochem Biophys Res Commun. 1996;225:427–35.CrossRefPubMed
6.
Zurück zum Zitat Yan W, Zhang W, You G, et al. Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group. Neuro Oncol. 2012;14:1432–40.PubMedCentralCrossRefPubMed Yan W, Zhang W, You G, et al. Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group. Neuro Oncol. 2012;14:1432–40.PubMedCentralCrossRefPubMed
7.
Zurück zum Zitat Zhang C, Zhang J, Hao J, et al. High level of miR-221/222 confers increased cell invasion and poor prognosis in glioma. J Transl Med. 2012;10:119.PubMedCentralCrossRefPubMed Zhang C, Zhang J, Hao J, et al. High level of miR-221/222 confers increased cell invasion and poor prognosis in glioma. J Transl Med. 2012;10:119.PubMedCentralCrossRefPubMed
8.
Zurück zum Zitat Choi HS, Yim SH, Xu HD, et al. Tropomyosin3 overexpression and a potential link to epithelial–mesenchymal transition in human hepatocellular carcinoma. BMC Cancer. 2010;10:122.PubMedCentralCrossRefPubMed Choi HS, Yim SH, Xu HD, et al. Tropomyosin3 overexpression and a potential link to epithelial–mesenchymal transition in human hepatocellular carcinoma. BMC Cancer. 2010;10:122.PubMedCentralCrossRefPubMed
9.
Zurück zum Zitat Brabletz T, Jung A, Reu S, et al. Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci U S A. 2001;98:10356–61.PubMedCentralCrossRefPubMed Brabletz T, Jung A, Reu S, et al. Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci U S A. 2001;98:10356–61.PubMedCentralCrossRefPubMed
10.
Zurück zum Zitat Kahlert UD, Nikkhah G, Maciaczyk J. Epithelial-to-mesenchymal(-like) transition as a relevant molecular event in malignant gliomas. Cancer Lett. 2013;331:131–8.CrossRefPubMed Kahlert UD, Nikkhah G, Maciaczyk J. Epithelial-to-mesenchymal(-like) transition as a relevant molecular event in malignant gliomas. Cancer Lett. 2013;331:131–8.CrossRefPubMed
11.
Zurück zum Zitat Brabletz T. To differentiate or not—routes towards metastasis. Nat Rev Cancer. 2012;12:425–36.CrossRefPubMed Brabletz T. To differentiate or not—routes towards metastasis. Nat Rev Cancer. 2012;12:425–36.CrossRefPubMed
13.
Zurück zum Zitat Qi S, Song Y, Peng Y, et al. ZEB2 mediates multiple pathways regulating cell proliferation, migration, invasion, and apoptosis in glioma. PLoS One. 2012;7:e38842.PubMedCentralCrossRefPubMed Qi S, Song Y, Peng Y, et al. ZEB2 mediates multiple pathways regulating cell proliferation, migration, invasion, and apoptosis in glioma. PLoS One. 2012;7:e38842.PubMedCentralCrossRefPubMed
14.
Zurück zum Zitat Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer. 2007;7:415–28.CrossRefPubMed Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer. 2007;7:415–28.CrossRefPubMed
15.
Zurück zum Zitat Bhat-Nakshatri P, Appaiah H, Ballas C, et al. SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/CD24− phenotype. BMC Cancer. 2010;10:411.PubMedCentralCrossRefPubMed Bhat-Nakshatri P, Appaiah H, Ballas C, et al. SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/CD24− phenotype. BMC Cancer. 2010;10:411.PubMedCentralCrossRefPubMed
16.
Zurück zum Zitat Han SP, Kim JH, Han ME, et al. SNAI1 is involved in the proliferation and migration of glioblastoma cells. Cell Mol Neurobiol. 2011;31:489–96.CrossRefPubMed Han SP, Kim JH, Han ME, et al. SNAI1 is involved in the proliferation and migration of glioblastoma cells. Cell Mol Neurobiol. 2011;31:489–96.CrossRefPubMed
17.
Zurück zum Zitat Weissenberger J, Priester M, Bernreuther C, et al. Dietary curcumin attenuates glioma growth in a syngeneic mouse model by inhibition of the JAK1,2/STAT3 signaling pathway. Clin Cancer Res. 2010;16:5781–95.CrossRefPubMed Weissenberger J, Priester M, Bernreuther C, et al. Dietary curcumin attenuates glioma growth in a syngeneic mouse model by inhibition of the JAK1,2/STAT3 signaling pathway. Clin Cancer Res. 2010;16:5781–95.CrossRefPubMed
18.
Zurück zum Zitat Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69:562–73.CrossRefPubMed Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69:562–73.CrossRefPubMed
19.
Zurück zum Zitat Surgucheva I, Chidambaram K, Willoughby DA, Surguchov A. Matrix metalloproteinase 9 expression: new regulatory elements. J Ocul Biol Dis Infor. 2010;3:41–52.PubMedCentralCrossRefPubMed Surgucheva I, Chidambaram K, Willoughby DA, Surguchov A. Matrix metalloproteinase 9 expression: new regulatory elements. J Ocul Biol Dis Infor. 2010;3:41–52.PubMedCentralCrossRefPubMed
20.
Zurück zum Zitat Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2:161–74.CrossRefPubMed Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2:161–74.CrossRefPubMed
21.
Zurück zum Zitat Comincini S, Paolillo M, Barbieri G, et al. Gene expression analysis of an EGFR indirectly related pathway identified PTEN and MMP9 as reliable diagnostic markers for human glial tumor specimens. J Biomed Biotechnol. 2009;2009:924565.PubMedCentralCrossRefPubMed Comincini S, Paolillo M, Barbieri G, et al. Gene expression analysis of an EGFR indirectly related pathway identified PTEN and MMP9 as reliable diagnostic markers for human glial tumor specimens. J Biomed Biotechnol. 2009;2009:924565.PubMedCentralCrossRefPubMed
22.
Zurück zum Zitat Yan W, Zhang W, Sun L, et al. Identification of MMP-9 specific microRNA expression profile as potential targets of anti-invasion therapy in glioblastoma multiforme. Brain Res. 2011;1411:108–15.PubMed Yan W, Zhang W, Sun L, et al. Identification of MMP-9 specific microRNA expression profile as potential targets of anti-invasion therapy in glioblastoma multiforme. Brain Res. 2011;1411:108–15.PubMed
23.
24.
Zurück zum Zitat Chu D, Zhang Z, Li Y, et al. Matrix metalloproteinase-9 is associated with disease-free survival and overall survival in patients with gastric cancer. Int J Cancer. 2011;129:887–95.CrossRefPubMed Chu D, Zhang Z, Li Y, et al. Matrix metalloproteinase-9 is associated with disease-free survival and overall survival in patients with gastric cancer. Int J Cancer. 2011;129:887–95.CrossRefPubMed
25.
Zurück zum Zitat Offersen BV, Knap MM, Horsman MR, Verheijen J, Hanemaaijer R, Overgaard J. Matrix metalloproteinase-9 measured in urine from bladder cancer patients is an independent prognostic marker of poor survival. Acta Oncol. 2010;49:1283–7.CrossRefPubMed Offersen BV, Knap MM, Horsman MR, Verheijen J, Hanemaaijer R, Overgaard J. Matrix metalloproteinase-9 measured in urine from bladder cancer patients is an independent prognostic marker of poor survival. Acta Oncol. 2010;49:1283–7.CrossRefPubMed
Metadaten
Titel
TPM3, a strong prognosis predictor, is involved in malignant progression through MMP family members and EMT-like activators in gliomas
verfasst von
Tao Tao
Yan Shi
Dongfeng Han
Wenkang Luan
Jin Qian
Junxia Zhang
Yingyi Wang
Yongping You
Chinese Glioma Cooperative Group (CGCG)
Publikationsdatum
01.09.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 9/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-1974-1

Weitere Artikel der Ausgabe 9/2014

Tumor Biology 9/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.